Skip to main content

news

Shardul Amarchand Mangaldas & Co (SAM) has advised private equity major Advent International on the purchase of a 50.1 percent stake in India’s Suven Pharmaceuticals, with Cyril Amarchand Mangaldas (CAM) advising the sellers, the Jasti family.

According to Reuters, Advent is expected to make an additional open offer for up to 26 percent of the voting share capital held by public shareholders. Advent intends to explore merging Suven with its wholly owned Cohance Lifesciences to build a company that specializes in active pharmaceutical ingredients as well as contract development and manufacturing businesses, Reuters added.

 

The CAM team was led by partner Shishir Vayttaden, with support from partners Namrata Kolar, Biplab Lenin, and Avaantika Kakkar.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Khaitan, SAM, Sidley advise on Torrent Power’s $413 mln QIP

by Nimitt Dixit |

Indian law firm Khaitan & Co has advised Torrent Power on its equity offering of $413 million through a qualified institutional placement of shares. Shardul Amarchand Mangaldas & Co and Sidley Austin advised the bookrunning lead managers on the deal.

Deals

IndusLaw guides Zepto’s $350 mln funding round

by Nimitt Dixit |

IndusLaw has guided Indian quick commerce company Zepto on its latest $350 million funding round led by Motilal Oswal's Private Wealth division.

Deals

9 firms advise on milestone $8.2 bln cross-border insurance deal

by Sarah Wong |

Global law firms Debevoise & Plimpton, Kirkland & Ellis and Herbert Smith Freehills are acting for Bermuda-based insurer Resolution Life on its $8.2 billion sale to Japan’s Nippon Life Insurance, the largest overseas acquisition by a Japanese insurer to date.